EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 336 filers reported holding EXELIXIS INC in Q4 2019. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,713,922 | +3.5% | 106,853 | +1.2% | 0.20% | +8.3% |
| Q3 2022 | $1,656,000 | -61.8% | 105,590 | -55.6% | 0.18% | -53.2% |
| Q2 2021 | $4,336,000 | +200.1% | 237,968 | +230.4% | 0.38% | +256.5% |
| Q4 2020 | $1,445,000 | -33.3% | 72,022 | -21.0% | 0.11% | -45.2% |
| Q2 2020 | $2,165,000 | +61.8% | 91,199 | +20.1% | 0.20% | +146.2% |
| Q4 2019 | $1,338,000 | -18.7% | 75,939 | -18.4% | 0.08% | -13.0% |
| Q3 2019 | $1,645,000 | – | 93,010 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |